PURPOSE: There is growing evidence that S-100B protein may be used as a novel biochemical marker of brain cell damage, measured by a simple blood test. In this paper, we summarize the current knowledge about S-100B serum measurements in severe head injury and address actual controversies. METHODS: The material of the present analysis consists of a MEDLINE literature search for S-100 and severe head injury from 1966 to 2003. Studies of S-100B in severe head injury were reviewed for their information about the potential clinical value of this marker. RESULTS: A total of 18 clinical studies were identified and reviewed. Peak values of serum S-100B were demonstrated to have the highest correlation to any endpoint parameter. Admission values also have a significant correlation to injury severity and outcome but show a highly time dependent temporal course. There is extracranial release of S-100B in multitrauma patients in the first 48 hours, but the impact is limited as many studies have found a clear relationship between S-100B and injury severity, imaging findings and outcome. CONCLUSION: S-100B belongs to a new generation of molecular serum markers of brain damage. These markers will have potential as a surrogate outcome marker or monitoring parameters for both clinical and experimental settings.
PURPOSE: There is growing evidence that S-100B protein may be used as a novel biochemical marker of brain cell damage, measured by a simple blood test. In this paper, we summarize the current knowledge about S-100B serum measurements in severe head injury and address actual controversies. METHODS: The material of the present analysis consists of a MEDLINE literature search for S-100 and severe head injury from 1966 to 2003. Studies of S-100B in severe head injury were reviewed for their information about the potential clinical value of this marker. RESULTS: A total of 18 clinical studies were identified and reviewed. Peak values of serum S-100B were demonstrated to have the highest correlation to any endpoint parameter. Admission values also have a significant correlation to injury severity and outcome but show a highly time dependent temporal course. There is extracranial release of S-100B in multitrauma patients in the first 48 hours, but the impact is limited as many studies have found a clear relationship between S-100B and injury severity, imaging findings and outcome. CONCLUSION:S-100B belongs to a new generation of molecular serum markers of brain damage. These markers will have potential as a surrogate outcome marker or monitoring parameters for both clinical and experimental settings.
Authors: Michael V DeFazio; Richard A Rammo; Jaime R Robles; Helen M Bramlett; W Dalton Dietrich; M Ross Bullock Journal: World Neurosurg Date: 2013-01-08 Impact factor: 2.104
Authors: Christian Friedrich Weber; Hannah Friedl; Michael Hueppe; Gudrun Hintereder; Thomas Schmitz-Rixen; Bernhard Zwissler; Dirk Meininger Journal: World J Surg Date: 2009-07 Impact factor: 3.352
Authors: Matthew J Rogatzki; Scott E Soja; Colleen A McCabe; Ryanne E Breckenridge; Jeffrey L White; Julien S Baker Journal: Int J Immunopathol Pharmacol Date: 2016-07-07 Impact factor: 3.219
Authors: Johan Undén; Ramona Astrand; Knut Waterloo; Tor Ingebrigtsen; Johan Bellner; Peter Reinstrup; Gunnar Andsberg; Bertil Romner Journal: Neurocrit Care Date: 2007 Impact factor: 3.532